Cardiac and peripheral actions of growth hormone and its releasing peptides: relevance for the treatment of cardiomyopathies.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Cardiovascular Research

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.CARDIORES.2005.08.022PMID 16219302
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting.

  2005cited by this paper
• Growth hormone-releasing peptide can improve left ventricular dysfunction and attenuate dilation in dilated cardiomyopathic hamsters.

  2004cited by this paper
• Six-months of recombinant human GH therapy in patients with ischemic cardiac failure

  2004cited by this paper
• Cardiac Stem Cell and Myocyte Aging, Heart Failure, and Insulin-Like Growth Factor-1 Overexpression

  2004cited by this paper
• Cardiovascular Effects of Growth Hormone Treatment: Potential Risks and Benefits

  2004cited by this paper
• Contribution of Akt and endothelial nitric oxide synthase to diazoxide-induced late preconditioning.

  2004cited by this paper
• Ghrelin in the heart and growth hormone: which is chicken, which is egg?

  2004influential reference
• The effects of GH replacement therapy on cardiac morphology and function, exercise capacity and serum lipids in elderly patients with GH deficiency

  2004cited by this paper
• Cardiac IGF-I manipulation by growth hormone following myocardial infarction.

  2004cited by this paper
• Left ventricular systolic dysfunction and ischemic cardiomyopathy.

  2003cited by this paper
• A Growth Hormone Secretagogue Prevents Ischemic-Induced Mortality Independently of the Growth Hormone Pathway in Dogs with Chronic Dilated Cardiomyopathy

  2003cited by this paper
• Molecular genetics of cardiomyopathy: changing times, shifting paradigms.

  2003cited by this paper
• Physical Repercussions of Childhood-Onset Growth Hormone (GH) Deficiency and hGH Treatment in Adulthood

  2003cited by this paper
• Effect of ghrelin and synthetic growth hormone secretagogues in normal and ischemic rat heart

  2003cited by this paper
• Administration of growth hormone to patients with advanced cardiac heart failure: effects upon left ventricular function, exercise capacity, and neurohormonal status.

  2003influential reference
• Cardiac dimension and function in patients with childhood onset growth hormone deficiency, before and after growth hormone retreatment in adult age.

  2003influential reference
• Growth hormone resistance in chronic heart failure and its therapeutic implications.

  2003cited by this paper
• Growth hormone induces eNOS expression and nitric oxide release in a cultured human endothelial cell line

  2003cited by this paper
• Nuclear Targeting of Akt Enhances Kinase Activity and Survival of Cardiomyocytes

  2003cited by this paper
• Growth hormone corrects vascular dysfunction in patients with chronic heart failure.

  2002influential reference
• Cardiac and Renal Effects of Growth Hormone in Volume Overload–Induced Heart Failure: Role of NO

  2002cited by this paper
• Cardiovascular and hormonal effects of subcutaneous administration of ghrelin, a novel growth hormone-releasing peptide, in healthy humans.

  2002cited by this paper
• GH‐independent cardiotropic activities of hexarelin in patients with severe left ventricular dysfunction due to dilated and ischemic cardiomyopathy

  2002influential reference
• Functional consequences of caspase activation in cardiac myocytes

  2002cited by this paper
• Losing heart: the role of apoptosis in heart disease—a novel therapeutic target?

  2002cited by this paper
• Growth hormone administration reduces circulating proinflammatory cytokines and soluble Fas/soluble Fas ligand system in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy.

  2002influential reference
• Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT

  2002cited by this paper
• Effects of early treatment with growth hormone on infarct size, survival, and cardiac gene expression after acute myocardial infarction.

  2002cited by this paper
• [Idiopathic cardiomyopathies].

  2002cited by this paper
• Effect of chronic treatment with bovine recombinant growth hormone on cardiac dysfunction and lesion progression in UM-X7.1 cardiomyopathic hamsters.

  2002cited by this paper
• Cardiomyopathies primitives : Insuffisances cardiaques

  2002cited by this paper
• Idiopathic dilated cardiomyopathy: a common but mystifying cause of heart failure.

  2002cited by this paper
• Ischemic versus non-ischemic heart failure: should the etiology be determined?

  2001cited by this paper
• Hemodynamic and histomorphometric characteristics of dilated cardiomyopathy of Syrian hamsters (Bio TO-2 strain).

  2001influential reference
• Ghrelin: discovery of the natural endogenous ligand for the growth hormone secretagogue receptor.

  2001cited by this paper
• Chronic Administration of Ghrelin Improves Left Ventricular Dysfunction and Attenuates Development of Cardiac Cachexia in Rats With Heart Failure

  2001cited by this paper
• Six months of recombinant human GH therapy in patients with ischemic cardiac failure does not influence left ventricular function and mass.

  2001cited by this paper
• Hexarelin protects H9c2 cardiomyocytes from doxorubicin-induced cell death

  2001cited by this paper
• Hemodynamic, renal, and hormonal effects of ghrelin infusion in patients with chronic heart failure.

  2001cited by this paper
• Growth Hormone Treatment in Dilated Cardiomyopathy

  2001cited by this paper
• Characterization of ultrastructure and its relation with DNA fragmentation in Fas‐induced apoptosis of cultured cardiac myocytes

  2001cited by this paper
• Commencing growth hormone replacement in adults with a fixed low dose. Effects on serum lipoproteins, glucose metabolism, body composition, and cardiovascular function.

  2001cited by this paper
• Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone.

  2001cited by this paper
• Similar cardiovascular effects of growth hormone and insulin-like growth factor-I in rats after experimental myocardial infarction.

  2001cited by this paper
• The role of apoptotic cell death in cardiovascular disease

  2001cited by this paper
• Growth hormone alone or combined with metoprolol preserves cardiac function after myocardial infarction in rats

  2001cited by this paper
• The somatotrophic system in patients with dilated cardiomyopathy: Relation of insulin‐like growth factor‐1 and its alterations during growth hormone therapy to cardiac function

  2000cited by this paper
• Growth Hormone Improves Bioenergetics and Decreases Catecholamines in Postinfarct Rat Hearts* *The study was supported by grants from the Swedish Heart and Lung Foundation, the Swedish Medical Research Council, Göteborg Medical Society, and the Medical Faculty at Göteborg University.

  2000cited by this paper
• Altered membrane proteins and permeability correlate with cardiac dysfunction in cardiomyopathic hamsters.

  2000cited by this paper
• Effects of growth hormone on renal renin gene expression in normal rats and rats with myocardial infarction.

  2000cited by this paper
• Effects of growth hormone on cardiac dysfunction and gene expression in genetic murine dilated cardiomyopathy

  2000cited by this paper
• Soluble Antiapoptotic Molecules and Immune Activation in Chronic Heart Failure and Unstable Angina Pectoris

  2000influential reference
• Evaluation of growth hormone administration in patients with chronic heart failure secondary to coronary artery disease.

  1999cited by this paper
• Growth hormone therapy in patients with dilated cardiomyopathy: preliminary observations of a pilot study.

  1999influential reference
• Insulin-Like Growth Factor I Improves Cardiovascular Function and Suppresses Apoptosis of Cardiomyocytes in Dilated Cardiomyopathy1.

  1999cited by this paper
• Treatment with growth hormone enhances contractile reserve and intracellular calcium transients in myocytes from rats with postinfarction heart failure.

  1999cited by this paper
• Recombinant growth hormone therapy in patients with ischemic cardiomyopathy : effects on hemodynamics, left ventricular function, and cardiopulmonary exercise capacity.

  1999cited by this paper
• Effects of Growth Hormone and Angiotensin-Converting Enzyme Inhibition Progressive Cardiac Dysfunction and Fibrosis in the Cardiomyopathic Hamster and

  1999cited by this paper
• Ischemic and nonischemic heart failure do not require different treatment strategies.

  1999cited by this paper
• Apoptosis in heart failure: release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy.

  1999cited by this paper
• Cardiac effects of hexarelin in hypopituitary adults.

  1999cited by this paper
• Nonischemic heart failure: epidemiology, pathophysiology, and progression of disease.

  1999cited by this paper
• Printed in U.S.A. Copyright © 1999 by The Endocrine Society Insulin-Like Growth Factor I Improves Cardiovascular Function and Suppresses Apoptosis of Cardiomyocytes in Dilated Cardiomyopathy*

  1999cited by this paper
• Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans

  1999cited by this paper
• Lack of beneficial effects of growth hormone treatment in conscious dogs during development of heart failure.

  1998cited by this paper
• A placebo-controlled study of growth hormone in patients with congestive heart failure.

  1998influential reference
• Differential effects of growth hormone on cardiomyocyte and extracellular matrix protein remodeling following experimental myocardial infarction.

  1998cited by this paper
• Sympathetic deactivation by growth hormone treatment in patients with dilated cardiomyopathy.

  1998cited by this paper
• Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy.

  1998influential reference
• Recombinant human growth hormone: old and novel uses.

  1998cited by this paper
• Regulation of cardiomyocyte apoptotic signaling by insulin-like growth factor I.

  1998cited by this paper
• The Growth Hormone Secretagogue Hexarelin Improves Cardiac Function in Rats After Experimental Myocardial Infarction

  1998cited by this paper
• Lack of beneficial effects of growth hormone treatment in conscious dogs during development of heart failure.

  1998cited by this paper
• Adults with childhood‐onset growth hormone deficiency: effects fo growth harmone treatment on cardiac structure

  1997influential reference
• [Epidemiology and natural history of cardiac failure].

  1997cited by this paper
• Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt

  1997cited by this paper
• Growth hormone improves cardiac function in rats with experimental myocardial infarction

  1997cited by this paper
• Growth hormone: a newcomer in cardiovascular medicine.

  1997cited by this paper
• Cardiac ischemia and impairment of vascular endothelium function in hearts from growth hormone-deficient rats: protection by hexarelin.

  1997cited by this paper
• Effect of growth hormone on cardiac function.

  1997cited by this paper
• Treatment of end-stage cardiac failure with growth hormone.

  1997cited by this paper
• Growth hormone attenuates early left ventricular remodeling and improves cardiac function in rats with large myocardial infarction.

  1997cited by this paper
• Cardiac ischemia and impairment of vascular endothelium function in hearts from GH-deficient rats: Protection by hexarelin

  1997cited by this paper
• GH replacement fails to improve ventricular function in hypophysectomized rats with myocardial infarction.

  1996cited by this paper
• Improved left ventricular function after growth hormone replacement in patients with hypopituitarism: Assessment with radionuclide angiography

  1996cited by this paper
• Depressed transient outward current density in ventricular myocytes from cardiomyopathic Syrian hamsters of different ages.

  1996influential reference
• Myocyte death in heart failure.

  1996cited by this paper
• A preliminary study of growth hormone in the treatment of dilated cardiomyopathy.

  1996cited by this paper
• Growth hormone in the treatment of dilated cardiomyopathy.

  1996influential reference
• Cardiovascular effects of insulin-like growth factor-1 and growth hormone in chronic left ventricular failure in the rat.

  1996influential reference
• Growth hormone improves cardiac performance in experimental heart failure.

  1995cited by this paper
• Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure.

  1995cited by this paper
• Three years of growth hormone treatment in growth hormone-deficient adults: near normalization of body composition and physical performance.

  1994cited by this paper
• Cardiovascular and renal effects of growth hormone *

  1994influential reference
• Bivalent effects of human growth hormone in experimental myocardial infarcts. Protective when administered alone and aggravating when combined with beta blockers.

  1990influential reference
• Hereditary polymyopathy and cardiomyopathy in the syrian hamster. I. Progression of heart and skeletal muscle lesions in the UM‐X7.1 line

  1982cited by this paper
• Cardiovascular Research

  1966cited by this paper

• Growth hormone-releasing hormone signaling and manifestations within the cardiovascular system

  2025cites this paper
• Design, Biological Characterization, and Discovery of Capromorelin Derivatives as Oral Growth Hormone Secretagogue Receptor Type 1a Agonist for the Treatment of Growth Hormone Deficiency.

  2025cites this paper
• Effects of growth hormone-releasing hormone deficiency in mice beyond growth

  2024cites this paper
• Ghrelin Derangements in Idiopathic Dilated Cardiomyopathy: Impact of Myocardial Disease Duration and Left Ventricular Ejection Fraction

  2019cites this paper
• Growth Hormone (GH) and Cardiovascular System

  2018cites this paper
• Hormone treatments in congestive heart failure

  2018cites this paper
• The CD36-PPARγ Pathway in Metabolic Disorders

  2018cites this paper
• Chronic limb-threatening ischemia could benefit from growth hormone therapy for wound healing and limb salvage

  2017cites this paper
• Growth hormone-releasing hormone attenuates cardiac hypertrophy and improves heart function in pressure overload-induced heart failure

  2017influential citation
• Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects

  2017cites this paper
• Growth hormone releasing peptide-6 (GHRP-6) and other related secretagogue synthetic peptides: A mine of medical potentialities for unmet medical needs

  2016cites this paper
• Acute growth hormone administration increases myoglobin expression and Glut4 translocation in rat cardiac muscle cells.

  2014cites this paper
• Agonists of growth hormone-releasing hormone stimulate self-renewal of cardiac stem cells and promote their survival

  2014cites this paper
• The cardiovascular action of hexarelin

  2014cites this paper
• Ghrelin As a Treatment for Cardiovascular Diseases

  2014cites this paper
• One dose of oral hexarelin protects chronic cardiac function after myocardial infarction.

  2014cites this paper
• HRT with Cardiovascular and Breast Cancer Risk Reduction

  2013cites this paper
• UNRAVELLING THE MECHANISM OF GHRELIN SECRETION AND THE EFFECTS OF GHRELIN REDUCTION USING A RECEPTOR DECOY APPROACH

  2013cites this paper
• Reproductive performance and fertility in male and female adult mice chronically treated with hexarelin.

  2012cites this paper
• Evaluation of pulsatile plasma concentrations of growth hormone in healthy dogs and dogs with dilated cardiomyopathy.

  2011cites this paper
• Gene expression in the right ventricle during development of pulmonary hypertension

  2011cites this paper
• A Crucial Role of Activin A-Mediated Growth Hormone Suppression in Mouse and Human Heart Failure

  2011cites this paper
• Insulin‐like growth factor axis (insulin‐like growth factor‐I/insulin‐like growth factor‐binding protein‐3) as a prognostic predictor of heart failure: association with adiponectin

  2010cites this paper
• Effects of hexarelin (a ghrelin analogue) on fertilisation and the pre- and postnatal development of mice.

  2010cites this paper
• Effects of GH secretagogues on contractility and Ca2+ homeostasis of isolated adult rat ventricular myocytes.

  2010cites this paper
• N-terminal pro-brain natriuretic peptide in newly diagnosed acromegaly

  2010cites this paper
• Cardioprotective effects of growth hormone-releasing hormone agonist after myocardial infarction

  2010cites this paper
• Growth hormone-releasing hormone: Extrapituitary effects in physiology and pathology

  2010cites this paper
• Régulation de l'activité transcriptionnelle de PPARgamma via l'activation des récepteurs CD36 et GHS-R1a : potentiel anti-athérosclérotique

  2010cites this paper
• Adult Rat Ventricular Myocytes Homeostasis of Isolated 2+ Effects of GH Secretagogues on Contractility and Ca

  2010cites this paper
• Integrating GHS into the Ghrelin System

  2010cites this paper
• Obestatin affords cardioprotection to the ischemic-reperfused isolated rat heart and inhibits apoptosis in cultures of similarly stressed cardiomyocytes.

  2010cites this paper
• Ghrelin and Cardiovascular Diseases

  2009cites this paper
• Desacyl‐ghrelin and synthetic GH‐secretagogues modulate the production of inflammatory cytokines in mouse microglia cells stimulated by β‐amyloid fibrils

  2009cites this paper
• Mecasermin (recombinant human insulin-like growth factor I)

  2009cites this paper
• Overexpression of TGFβ1 by adeno-associated virus type-2 vector protects myocardium from ischemia–reperfusion injury

  2008cites this paper
• Hexarelin Signaling to PPARγ in Metabolic Diseases

  2008influential citation
• Overexpression of TGFbeta1 by adeno-associated virus type-2 vector protects myocardium from ischemia-reperfusion injury.

  2008cites this paper
• Cardiac, skeletal, and smooth muscle regulation by ghrelin.

  2008cites this paper
• ROLE OF INSULIN‐LIKE GROWTH FACTOR 1 AND PHOSPHOINOSITIDE 3‐KINASE IN A SETTING OF HEART DISEASE

  2008cites this paper
• POTENTIAL NON-GROWTH USES OF rhIGF-I.

  2007cites this paper
• A Growth Hormone-Releasing Peptide that Binds Scavenger Receptor CD36 and Ghrelin Receptor Up-Regulates Sterol Transporters and Cholesterol Efflux in Macrophages through a Peroxisome Proliferator-Activated Receptor -Dependent Pathway

  2006cites this paper
• A growth hormone-releasing peptide that binds scavenger receptor CD36 and ghrelin receptor up-regulates sterol transporters and cholesterol efflux in macrophages through a peroxisome proliferator-activated receptor gamma-dependent pathway.

  2006cites this paper